Effect of Thromboxane Synthetase Inhibition on Canine Autogenous Vein Grafts

ERIC D. ENDEAN, M.D., JEFFREY M. BOORSTEIN, B.S., PAUL L. HEES, B.S., AND JACK L. CRONENWETT, M.D.1

Department of Surgery, University of Michigan Medical Center, Ann Arbor, Michigan 48109, and Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire 03756

Presented at the Annual Meeting of the Association for Academic Surgery, Cincinnati, Ohio, November 10-13, 1985

This study examined the effect of an orally active thromboxane (TXA2) synthetase inhibitor (TSI) on the patency, TXA2 production, and platelet accumulation of reversed autogenous vein grafts. Ten dogs received TSI (U-63557A) 10 mg/kg po q8 hr for 6 weeks, beginning 24 hr prior to surgery, while 15 control dogs were untreated. One jugular vein was harvested and stored in 37°C saline for 1 hr to induce mild endothelial injury (stored). Normal and stored jugular vein grafts (8 cm) were then implanted in opposite femoral arteries while 3-cm segments of the same veins were implanted in the carotid arteries. Femoral graft flow was restricted with a 5 Fr distal arterial stenosis and patency determined by arteriography at 1, 2, 4, and 6 weeks. Vein graft endothelial surface TXB2 production was measured by RIA at graft implantation and in carotid grafts harvested at 1 week. 111In-labeled platelets were given iv 24 hr prior to carotid graft harvest to determine graft-platelet deposition. TSI treatment improved early (1 week) femoral vein graft patency from 63 to 89% (P < 0.05), a trend that persisted for 6 weeks. Warm saline storage reduced 1-week graft patency from 83 to 63% (P < 0.05), a difference that decreased with time. TSI treatment resulted in a marked decrease in TXB2 production, but was not associated with decreased 111In-labeled platelet deposition in carotid vein grafts. Warm saline storage increased graft-platelet deposition which was predominant at the arterial anastomoses. TSI treatment may improve early vein graft patency during the transient period of endothelial injury.

INTRODUCTION

Aspirin is frequently used as an antiplatelet agent in an attempt to improve the patency rate of small diameter vascular grafts. Such cyclooxygenase inhibitors, however, have the theoretical disadvantage of inhibiting prostacyclin (PGI2) production in addition to thromboxane A2 (TXA2) synthesis. This criticism has stimulated the development of selective thromboxane synthetase inhibitors (TSIs) which may increase PGI2 production by redirecting endoperoxide precursors that accumulate during TXA2 inhibition [11]. Since autogenous vein grafts retain the ability to synthesize PGI2 [6], we hypothesized that TSI treatment would be more beneficial for these grafts than for prosthetic grafts. This study was designed to test the ability of a new TSI, U-63557A [24], to enhance the patency rate of autogenous vein grafts in the canine femoral artery circulation. The in vivo production of TXB2 (the stable metabolite of TXA2) and platelet accumulation on vein graft surfaces were measured to correlate with the effect of U-63557A on graft patency.

METHODS

Graft patency determination. Twenty-five adult mongrel dogs of both sexes (18-30 kg) were divided into control (n = 15) and treatment (n = 10) groups. Treatment dogs received U-63557A [sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate], an orally active TSI, 10 mg/kg po q8 hr beginning 24 hr prior to surgery and continuing for the 6-week duration of study. Control dogs received no treatment. After iv thiamyl induction,
dogs were anesthetized with halothane, nitrous oxide, and oxygen inhalation for graft implantation. Using sterile technique, the femoral and carotid arteries and external jugular veins were exposed bilaterally. Both jugular veins were harvested to provide an 8-cm segment for superficial femoral artery (SFA) implantation in all dogs; a 3-cm segment for common carotid artery implantation in six treated and eight control dogs; and a 2-cm segment for baseline TXB₂ assay in all dogs. One of the jugular veins was removed for immediate implantation without storage, distention, or irrigation, while the contralateral jugular vein was placed in 37°C normal saline storage for 1 hr in an attempt to induce endothelial damage. Vein grafts placed in the femoral location were reversed and anastomosed in an end-to-side fashion using continuous 6-0 polypropylene suture with spatulation of the anastomoses, from the proximal SFA, immediately distal to the profunda branch, to a point in the SFA 8 cm distally. A 5 Fr ligature was placed around the distal SFA in order to reproducibly restrict graft outflow. The mid portion of the SFA was ligated to completely divert blood flow through the vein graft. Vein grafts placed in the common carotid arteries were reversed and anastomosed in an end-to-end fashion using continuous 6-0 polypropylene suture with spatulation of the anastomoses, from the proximal SFA, immediately distal to the profunda branch, to a point in the SFA 8 cm distally. A 5 Fr ligature was placed around the distal SFA in order to reproducibly restrict graft outflow. The mid portion of the SFA was ligated to completely divert blood flow through the vein graft. Vein grafts placed in the common carotid arteries were reversed and anastomosed in an end-to-end fashion using continuous 6-0 polypropylene suture. Femoral and carotid vein grafts were simultaneously implanted by two operating teams to ensure equivalent graft treatment and storage time. The jugular vein removed for immediate use (normal vein) was implanted on one side in both the carotid and femoral locations, while the jugular vein selected for I-hr warm saline storage (stored vein) was implanted into the contralateral carotid and femoral artery locations.

A midline, lower abdominal incision was used to expose the middle sacral artery. An INFUSAID injection port was implanted in a subcutaneous pocket in the lower abdomen and its Silastic catheter placed just inside the infrarenal aorta via the middle sacral artery for subsequent arteriography. The surgical incisions were closed and the dogs recovered from anesthesia. Normal saline (1–1.5 l iv) was administered during the 3-hr operative procedure, and penicillin-G plus streptomycin were administered im preoperatively and on Postoperative Days 1 and 2.

Arteriograms were obtained under brief thiamylal sodium anesthesia at 24 hr and at 1, 2, 4, and 6 weeks postoperatively. Renografin-76 (20 ml) was injected into the infrarenal aorta via the subcutaneous injection port and a single timed X-ray exposure was made to visualize the femoral artery grafts.

Graft platelet deposition. The subset of dogs that received carotid vein grafts underwent indium-111 oxine platelet labeling on Postoperative Day 6. Platelet labeling was performed using a modification of the technique of Thakur et al. [23]. Venous blood was drawn through a large bore needle into plastic syringes containing two different anticoagulants (36 ml blood:4 ml acid citrate dextrose (ACD); 18 ml blood:2 ml 3.8% sodium citrate). After centrifugation of these separate samples at 200g for 10 min, platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were isolated. Both ACD and sodium citrate-prepared PRP were then centrifuged at 100g for 10 min. Traces of ACD plasma in the platelet button were eliminated by twice layering and removing 2 ml of modified Tyrodes solution (MTS) [23] at 37°C. Platelet pellets were then suspended in 4 ml MTS at 37°C and 500 mCi (0.5 ml) of ¹¹⁹In oxine (Amersham, saline solution) was added dropwise to the platelet suspension. Platelets were then incubated at 37°C for 10 min, and 4 ml of ACD-prepared PPP was added prior to 7-min centrifugation at 1000g to remove any unbound oxine. The labeled platelets were finally resuspended in 4 ml of sodium citrate-prepared PPP for iv reinjection into the animal.

One day later, the dogs were reanesthetized (thiamylal sodium), the neck incisions reexplored, and the carotid vein grafts harvested to include a 1-cm segment of proximal and distal native carotid artery. After removal, the graft segments and adjacent carotid artery were gently flushed with normal saline to remove any contained blood. The grafts were then di-
vided into five segments, 1 cm in length, consisting of proximal and distal native carotid artery, proximal and distal anastomoses, and central vein graft. Each sample was weighed and subsequently counted for \(^{111}\)In activity in a gamma well counter. A sample of blood was removed at the time of carotid graft harvest and also counted to determine the \(^{111}\)In activity of circulating platelets. Since graft and artery diameters were uniform in these dogs, small variations in the length of the counted graft and artery segments were normalized by dividing the counts per segment by the segment weight. Platelet deposition was expressed as the ratio of the \(^{111}\)In counts per gram of graft (artery) segment divided by the counts per 100 \(\mu\)l of circulating blood.

Thromboxane production. Luminal vein graft TXB\(_2\) production was measured using a technique suggested by Eldor et al. [12]. The segment of vein to be analyzed was incised longitudinally to expose the endothelial surface, which was gently but thoroughly irrigated with Tris buffer (pH 7.4). The vein segment was then clamped in a plastic template which exposed a 0.79-cm\(^2\) endothelial surface area to a 2-cm-deep circular well which was filled with 1 ml Tris buffer at \(37^\circ\)C. The vein graft was incubated in this template for 30 min at \(37^\circ\)C, after which the buffer was removed and frozen for subsequent TXB\(_2\) radioimmunoassay [13]. Vein graft TXB\(_2\) production was measured at the time of graft implantation from both immediately implanted and warm saline-stored graft segments, as well as from vein grafts harvested after 1 week of carotid implantation. The central portion of the carotid vein graft was used for this determination prior to the determination of its \(^{111}\)In activity.

Statistical analysis. Vein graft patency was analyzed by product moment actuarial technique with significant differences determined by the Wilcoxon test. Patency at individual time points for TSI-treated and control dogs was tested by the Fisher exact test for independent samples, while differences between immediately implanted and warm saline-stored grafts were tested by the McNemar test for paired data [9]. TXB\(_2\) production and \(^{111}\)In platelet deposition were compared between treatment groups by the Mann--Whitney test and within treatment groups by the Wilcoxon sign ranks test (all two-tail analyses) [9]. Correlation between graft patency, TXB\(_2\) production, and platelet deposition was measured by the Spearman rank correlation coefficient.

RESULTS

In this canine model, autogenous jugular vein grafts placed in the femoral artery location demonstrated 6-week cumulative patency rates of 53 to 70%. Most graft occlusions occurred during the first 2 weeks of implantation, with only 2 of 50 grafts occluding between 2 and 6 weeks (Fig. 1). TSI treatment appeared to improve the patency of both normal and warm saline stored vein grafts when compared with untreated control dogs, although actuarial analysis of these survival curves did not demonstrate statistical significance (Wilcoxon test). The effect of TSI was most apparent 1 week after graft implantation when normal vein grafts in control dogs demonstrated a 27% lower patency than in TSI-treated dogs \((P = 0.13, \text{ Fisher exact test, Table 1})\). This nearly significant difference also existed for saline stored grafts, which had a 27% lower 1-week patency in control dogs compared with TSI-treated dogs \((P = 0.20, \text{ Fisher exact test, Table 1})\). In addition to the effect of drug treatment

---

**Fig. 1.** Femoral artery autogenous vein graft patency in 15 control and 10 thromboxane synthetase inhibitor (TSI)-treated dogs (means ± SEM). Normal and warm saline-stored vein grafts were placed in contralateral sides in each animal.
TABLE 1
FEMORAL ARTERY AUTOGNEOUS VEIN GRAFT PATENCY (%)

<table>
<thead>
<tr>
<th></th>
<th>1 week</th>
<th>6 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal vein</td>
<td>Stored vein</td>
</tr>
<tr>
<td>Control</td>
<td>73%</td>
<td>53%</td>
</tr>
<tr>
<td></td>
<td>( P = 0.20^{**})</td>
<td>( P = 0.12^*)</td>
</tr>
<tr>
<td>TSI treated</td>
<td>100%</td>
<td>80%</td>
</tr>
<tr>
<td></td>
<td>( P = 0.15^{**})</td>
<td>ns^*</td>
</tr>
</tbody>
</table>

* Fisher exact test for independent samples (two tailed).
** McNemar test for paired data (two tailed).

on graft patency, warm saline storage reduced 1-week graft patency by 20% in both TSI-treated and control dogs. These differences, which approached statistical significance at 1 week, were nearly eliminated by 6 weeks, when normal and saline-stored veins had comparable patency rates (Table 1).

Graft and treatment subgroups were combined to evaluate the effect of TSI treatment on both normal and saline-stored vein grafts \( (n = 30\) control, \( n = 20\) treatment), as well as the effect of warm saline storage on both control and TSI treated dogs \( (n = 25\) normal, \( n = 25\) stored vein grafts). TSI treatment improved early (1 week) vein graft patency from 63 to 89% (Fig. 2, \( P < 0.05\), Fisher exact test). Although this effect persisted for 6 weeks, the difference in overall survival curves only approached statistical significance \( (P = 0.21\), Wilcoxon test). Warm saline storage reduced 1-week graft patency from 83 to 63% (Fig. 3, \( P < 0.05\), McNemar test). This difference subsequently decreased with time, however, so that no difference existed between normal and saline-stored grafts at 6 weeks \( (P = 0.31\), Wilcoxon test).

Vein graft TXB\(_2\) production was three to seven times lower in TSI-treated dogs than in control dogs when assayed at implantation and at 1 week postoperatively (Table 2). These reductions were highly significant for both normal and warm saline-stored grafts. TXB\(_2\) production increased three- to sevenfold in all vein grafts removed at 1 week compared with the same grafts at implantation. There was no significant difference in TXB\(_2\) production, however, between normal and saline-stored vein grafts at implantation or at 1 week postoperatively (Table 2).

In-labeled platelet deposition occurred predominantly at the proximal and distal carotid vein graft anastomoses. There was no significant difference in platelet deposition between the proximal and distal carotid artery segments and the midportion of normal jugular vein grafts in control dogs (Table 3). Significantly increased platelet deposition did oc-

![Fig. 2. Patency of all femoral vein grafts (both normal and saline stored) in control versus thromboxane synthase inhibitor (TSI)-treated dogs (means ± SEM). At 1 week, \( P < 0.05\), Fisher exact test.](image)
increased platelet deposition in both the graft and the anastomoses when compared with proximal or distal native artery (Table 3).

There was no correlation ($r_s < 0.2$) between platelet deposition (vein graft or anastomoses) and TXB$_2$ production at the time of carotid vein graft harvest. Furthermore, there was no correlation between vein graft TXB$_2$ production or platelet deposition and 1- or 6-week patency of comparably treated femoral artery grafts in the same animals.

**DISCUSSION**

In contrast to aspirin and other cyclooxygenase inhibitors, selective inhibition of TXA$_2$ synthetase has the theoretical advantage of preserving or increasing PGI$_2$ production. Accumulated endoperoxides resulting from TXA$_2$ inhibition appear to be redirected to enhance PGI$_2$ synthesis when PGI$_2$ synthetase is available [8, 10, 11]. Despite this potential advantage, TSIs do not inhibit in vitro platelet aggregation as consistently as aspirin [8]. This may be due to the proaggregatory activity of certain endoperoxide intermediates that do not accumulate after cyclooxygenase inhibition [10]. These considerations suggest that selective TXA$_2$ inhibition would have maximum advantage over cyclooxygenase inhibition in conjunction with autogenous tissue that is capable of PGI$_2$ generation.

Despite these theoretical objections, aspirin

---

**TABLE 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Normal vein grafts$^a$</th>
<th>Stored vein grafts$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>TSI treated</td>
</tr>
<tr>
<td>Implantation</td>
<td>431 ± 58</td>
<td>129 ± 57</td>
</tr>
<tr>
<td>1 week postoperative</td>
<td>2727 ± 1065</td>
<td>378 ± 86</td>
</tr>
</tbody>
</table>

*Note. Values are means ± SEM.

* $P < 0.03$, Implantation vs 1 week, Wilcoxon sign ranks test.

$^a$ Normal vs stored vein grafts, no significant differences, Wilcoxon sign ranks test.

$^b$ Control vs TSI-treated dogs, Mann–Whitney test.
TABLE 3

PLATELET-GRAFT DEPOSITION (COUNTS $^{111}$In/g GRAFT ÷ COUNTS $^{111}$In/100 µl BLOOD)

<table>
<thead>
<tr>
<th></th>
<th>Proximal artery</th>
<th>Proximal anastomosis</th>
<th>Vein graft</th>
<th>Distal anastomosis</th>
<th>Distal artery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Control dogs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal vein</td>
<td>5.8 ± 1.0</td>
<td><strong>13.9 ± 2.9</strong></td>
<td>*5.3 ± 1.1</td>
<td><strong>13.7 ± 1.6</strong></td>
<td>5.7 ± 1.1</td>
</tr>
<tr>
<td>Stored vein</td>
<td>6.3 ± 1.0</td>
<td>*<strong>30.4 ± 7.0</strong></td>
<td><strong>20.3 ± 6.2</strong></td>
<td><strong>21.7 ± 3.7</strong></td>
<td>9.1 ± 2.1</td>
</tr>
<tr>
<td><strong>TSI-treated dogs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal vein</td>
<td>5.8 ± 0.8</td>
<td><strong>16.3 ± 4.1</strong></td>
<td><strong>10.2 ± 1.0</strong></td>
<td><strong>16.1 ± 4.1</strong></td>
<td>5.5 ± 1.2</td>
</tr>
<tr>
<td>Stored vein</td>
<td>8.7 ± 2.1</td>
<td><strong>22.7 ± 4.4</strong></td>
<td><strong>18.8 ± 3.6</strong></td>
<td><strong>27.3 ± 6.3</strong></td>
<td>8.6 ± 2.4</td>
</tr>
</tbody>
</table>

* $P < 0.10$, **$P < 0.05$, ***$P < 0.025$, Wilcoxon sign-ranks test (two tail). #$P < 0.02$, control vs TSI-treated dogs for normal vein grafts, Mann-Whitney test. Other control vs treated dog comparisons all nonsignificant ($P > 0.10$).

(often combined with dipyridamole) has improved aortocoronary vein graft patency in some clinical trials and has reduced vein graft anastomotic intimal fibroplasia in experimental models [6, 20]. In contrast, aspirin treatment in rabbit endothelial injury models inhibited endothelial healing, enhanced platelet accumulation, and reduced PGI$_2$ production [3, 4]. Treatment of injured rabbit endothelium with TSI, however, reduced platelet deposition and enhanced PGI$_2$ synthesis [10, 16, 21]. Furthermore, aspirin-dipyridamole did not increase the patency rate of lower extremity autogenous vein grafts in humans [19]. Since vein graft occlusion remains a significant clinical problem, the above considerations suggested our study of the effect of selective TXA$_2$ inhibition on vein graft patency.

Although TSI caused a marked reduction of TXB$_2$ production in our study, its ability to improve vein graft patency was only modest. Furthermore, even though improved early graft patency was seen in TSI-treated dogs, no corresponding reduction in graft-platelet deposition was demonstrated. Since vein grafts do not accumulate sufficient $^{111}$In-labeled platelets for external gamma camera imaging, it was necessary to remove vein grafts to measure platelet deposition in a well counter. This prevented the measurement of graft patency and platelet deposition in the same graft and led to the use of carotid and femoral artery sites in our model. In retrospect, differences in anastomotic technique, graft length, and blood flow rate might have caused predictable differences in platelet deposition between femoral and carotid artery grafts. Although we did not measure graft flow rates, femoral outflow stenosis almost certainly caused significantly lower graft blood flow in the femoral than in the carotid location. Since lower flow rates increase platelet graft deposition [7], measurement of platelet deposition in the femoral grafts themselves might have correlated better with early improved femoral graft patency in TSI-treated dogs. These results,
therefore, should not be interpreted as disproving a relationship between TSI effects on graft patency and a potential anti-platelet mechanism.

Our finding of improved early vein graft patency after TSI treatment is supported by a recent report of Bergquist et al. [2]. These investigators demonstrated that dazoxiben, an imidoazole-derived TSI, improved the patency of human umbilical vein grafts after 4 hr of \textit{ex vivo} perfusion in sheep. Decreased platelet deposition and thrombus weight were associated with decreased TXB$_2$ production. Dazoxiben and other TSIs have also been shown to reduce platelet adhesion on endothelium damaged rabbit arteries and to reduce TXB$_2$ but increase PGI$_2$ production [10, 21]. A significant effect of TSI treatment was not seen with Dacron grafts, however, where dazoxiben failed to reduce platelet deposition in an \textit{ex vivo} perfusion circuit or in baboon A-V shunts, despite reduced TXB$_2$ production [14, 17]. These observations suggest that endogenous PGI$_2$ production, not present in prosthetic grafts, may be essential for TSI efficacy. This has been demonstrated in a canine coronary artery stenosis model in which effective TSI prevention of platelet aggregation was blocked by cyclooxygenase inhibition that prevented PGI$_2$ production [1, 15]. U-63557A, the TSI used in this study, has been shown to significantly reduce TXB$_2$ production in dogs, monkeys, and humans without tachyphylaxis after 14 days of oral administration [15]. A dose of 10 mg/kg markedly reduced TXB$_2$ production in dogs for 4 to 6 hr [24]. Recent experience in our laboratory suggests that a larger dose of U-63557A might have had more beneficial effects in this study.

Vein graft storage in 37°C saline was used in our study to produce a mild endothelial injury analogous to some clinical settings. LoGerfo et al. reported that such storage resulted in early endothelial disruption and platelet–leukocyte adhesion, with subsequent medial thickening [18]. Although we did not examine these morphologic changes, warm saline storage was associated with reduced vein graft patency and increased platelet accumulation 1 week after implantation, during the time when endothelial injury exists, according to LoGerfo et al. Elimination of the saline storage effect on 4- to 6-week graft patency corresponds to the time course of endothelial healing after this degree of vein injury [18]. The basis for increased TXB$_2$ production after 1 week of vein graft implantation was not specifically investigated in this study. We speculate that this increased production may have resulted from increased luminal accumulation of platelets, monocytes, and leukocytes during the first postoperative week that were not present when vein grafts were implanted. Although arteries and veins have been shown to synthesize TXA$_2$ in addition to their more predominant PGI$_2$ production [22], electron microscopy of the vein graft luminal surface would be necessary to exclude a major TXA$_2$ contribution from adherent blood elements. The use of femoral artery outflow stenosis to reduce autogenous vein graft patency resulted in a 6-week graft patency rate of 53 to 58% in control dogs. Since no grafts occluded between 4 and 6 weeks, this appears to be a practical model to investigate vein graft patency in a 4-week study in dogs. Such a technique is necessary since unrestricted flow through canine autogenous vein grafts nearly always results in 100% long-term patency, making such an animal model impractical for a study with graft occlusion as the endpoint. Although it is generally accepted that platelet–graft interaction is an important contributor to arterial graft failure, it is equally clear that many factors influence early and late graft patency. Since we do not yet have data concerning the ability of aspirin or other cyclooxygenase inhibitors to improve the patency of vein grafts in this particular animal model, it is difficult to judge the significance of the improvement seen with TSI in this report. The ability of TSI to improve early vein graft patency, during the period of maximal, but transient endothelial injury and decreased PGI$_2$ production, however, might be important. These results should stimulate a comparison
of the chronic effects of both TSI and aspirin on graft patency and platelet deposition in an appropriate animal model.

ACKNOWLEDGMENTS
This study was supported in part by NIH grant HL-35102. U-63557A was provided by the Upjohn Company.

REFERENCES